Tevogen Bio Welcomes Victor Sordillo, Renowned Global Safety Management Expert, to its Board of Directors
Summary
“It’s an honor to have the opportunity to provide insight and leadership alongside other members of the Board, and I look forward to contributing to Tevogen’s patient-centric mission to develop convenient and affordable immunotherapies for large patient populations, while continuing the expansion of the company’s novel and disruptive biotech business model, which has the potential to integrate affordability with business sustainability.” “Victor’s addition to the Board will allow us to leverage his vast industry expertise, commitment to increasing the accessibility of lifesaving medications, and compassionate spirit, as we continue to pioneer the next era of medical innovation,” said Tevogen Bio CEO, Ryan Saadi, M.D., M.P.H. Tevogen Bio is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen Bio’s goal is to provide access to the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.